NISCAIR Online Periodicals Repository

NISCAIR ONLINE PERIODICALS REPOSITORY (NOPR)  >
NISCAIR PUBLICATIONS >
Research Journals >
Journal of Scientific and Industrial Research (JSIR) >
JSIR Vol.63 [2004] >
JSIR Vol.63(03) [March 2004] >


Title: Targeted drug delivery (Site specific drug delivery)
Authors: Pandey, Archana
Mishra, Satyendra
Tiwari, Alka
Misra, Krishna
Keywords: Targeted validation
Genomics
Proteomics
Aptamers
Ribozymes
DNA
Micro array
Issue Date: Mar-2004
Publisher: CSIR
IPC CodeInt Cl.7: A 61 P 43/00
Abstract: The conventional drugs used so far are small organic molecules meant to degrade the diseased protein, formed as a result of the interference of pathogens at cellular level. A high concentration of these drugs in the cells is necessary for desired therapeutic effect. This aggravates the problem of toxicity. Ever since the unraveling of human genome, attempts are being made to target the drugs selectively to the affected sites in order to increase their efficiency and simultaneously decrease their side effects. ‘Proteomics’ and ‘genomics’ have emerged as new disciplines. The ‘target identification’ for any ligand (drug) can now be achieved by identification of ‘right gene’, ‘right pathway’ and ‘right target,’ and the ‘right drug’ for ‘right patient’ can be developed. Genomics information decides the target validation, which is, in fact the association between particular target and disease process. Target validation can be achieved either at DNA level using gene knockout strategies and triplex formation, at RNA level using RNA interference (RNAi), at m-RNA level using antisense concept, at ribozyme level or at any other intermediate growth promoter site. Target validation is also possible via DNA- microarrays, stem cells or monoclonal antibodies. Recently, stem cells are being used for target identification and drug development. The application of aptamers, i.e., nucleic acids having well defined 3-D shape is gaining importance in target validation of drugs. The application of the knowledge of ‘Proteomics’, Transproteomics and ‘Genomics’ together with the array approach is likely to decide the future of drug development.
Page(s): 230-247
ISSN: 0975-1084 (Online); 0022-4456 (Print)
Source:JSIR Vol.63(03) [March 2004]

Files in This Item:

File Description SizeFormat
JSIR 63(3) 230-247.pdf272.87 kBAdobe PDFView/Open
 Current Page Visits: 914 
Recommend this item

 

National Knowledge Resources Consortium |  NISCAIR Website |  Contact us |  Feedback

Disclaimer: NISCAIR assumes no responsibility for the statements and opinions advanced by contributors. The editorial staff in its work of examining papers received for publication is helped, in an honorary capacity, by many distinguished engineers and scientists.

CC License Except where otherwise noted, the Articles on this site are licensed under Creative Commons License: CC Attribution-Noncommercial-No Derivative Works 2.5 India

Copyright © 2012 The Council of Scientific and Industrial Research, New Delhi. All rights reserved.

Powered by DSpace Copyright © 2002-2007 MIT and Hewlett-Packard | Compliant to OAI-PMH V 2.0

Home Page Total Visits: 575748 since 06-Feb-2009  Last updated on 26-Aug-2014Webmaster: nopr@niscair.res.in